Cidara Therapeutics Announces Offering of Common Stock and Warrants

SAN DIEGO, May 21, 2018 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has entered into a securities purchase agreement with certain investors providing for the purchase and sale, in a registered direct offering, of up to an aggregate of $120.0 million of its common stock, in three closings. Cidara will offer 10,638,297 shares of common stock in the first closing of the offering at a price of $4.70 per share, for aggregate gross proceeds to Cidara of approximately $50.0 million, before deducting fees to the placement agents and other estimated offering expenses payable …

READ FULL TEXT

Leave a Reply

Your email address will not be published.